News

Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quart

Biogen (NASDAQ:BIIB) executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth. Speaking at a Wells Fargo conference, Chief Financial Officer Robin Kramer said B

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...

Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...

Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track...

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026. The deal lands just over a week after the company posted a second-quarter beat that sent shares up nearly 5% on July 29. Together, the two moments […]

In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Veeva Systems Inc (VEEV) reports $928 million in revenue and best-ever CRM performance, with Veeva Falcon AI gaining traction.

Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment

Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 14.4% to $218.22 per share while the index has gained 10.5%.

Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. See our latest analysis for Biogen. Biogen's recent guidance upgrade comes after a period of renewed momentum, with the share price at US$214.35 and a 30 day share price return of about 8%, while the 1 year total shareholder return of around 54% contrasts with weaker 3 and 5 year total shareholder returns. This...

In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio. This improved outlook, combined with investor attention on five upcoming Phase 3 readouts in lupus, transplant, and rare disease programs, has become a central focus in reassessing the company’s long-term profile. Next, we’ll examine how Biogen’s higher earnings guidance and advancing...

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

Biogen has notably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge.

Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations reported to date. Speaking at a Canaccord Genuity event, Chief Executive Officer Ian Smith said t

Growth portfolio revenue surpassed legacy MS franchise for second consecutive quarter.

Biogen is one of the oldest and most venerable biotechs. For a time in the late 1990s, Biogen's share price grew ninefold.

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.

Biogen Inc. has released its second-quarter 2026 results, reporting revenue of US$2.74 billion versus US$2.65 billion a year earlier, while net income dropped to US$97.5 million and diluted EPS from continuing operations fell to US$0.66 from US$4.33. Despite modest revenue growth for both the quarter and first half of 2026, Biogen’s profitability compressed sharply, with six‑month net income falling to US$417.0 million from US$875.3 million, highlighting a widening gap between sales...

The company published its second-quarter results on Wednesday morning.

Biogen Inc (BIIB) reports a 3% revenue increase, driven by a robust growth portfolio and strategic acquisitions, despite facing market challenges.

Moby summary of Biogen Inc.'s Q2 2026 earnings call

Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results. Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company’s growth port

Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.